International Medical Journal, Vol. 25., Iss. 2, 2019, P. 76−80.
IMMEDIATE RESULTS OF TREATMENT WITH NUCLEOTIDE/NUCLEOSIDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
Mykolayiv Regional Infectious Diseases Hospital, Ukraine
Owing to the scientific achievements of recent decades it has been possible to significantly expand the idea of the pathogenesis of chronic hepatitis B, which made it possible to develop effective methods for the disease diagnosis, to identify the main therapeutic directions in its treatment and significantly improve the prognosis. The direct results of treatment with nucleotide / nucleoside analogues in viral hepatitis B were analyzed. The study included patients with HBsAg−positive viral hepatitis B who received lamivudine 100 mg/day and patients prescrivbed with tenofovir 300 mg/day. The duration of prospective observation was 48−52 weeks. The laboratory (alanine aminotransferase content) and virologic (HBsAg, qualitative and quantitative determination of HBV DNA by polymerase chain reaction) were performed in local laboratories. The indices of viral load and virological response were considered as the endpoints. A complete virologic response was considered to be the level of HBV DNA < 300 copies/ml and the normalization of the level of alanine aminotransferase at the end of treatment. The results of this study showed that the total number of patients with complete virological response (HBV DNA < 300 copies/ml) did not differ after 4 weeks in the lamivudine and tenofovir groups; after 24 weeks of prospective observation, the frequency of complete virological response in the tenofovir group was 25.2 % more, and the overall level of complete virological response in 48−52 weeks after initiation of antiviral therapy was 46.4 % in the lamivudine group and 74.2 % in the tenofovir group.
Key words: hepatitis B, HBsAg−positive, lamivudine, tenofovir, alanine aminotransferase, virologic response.